Dr. Laurie Smaldone Alsup M.D. serves as Independent Director of the Company.D. serves as Independent Director of the Company.D. serves as Independent Director of the Company. Dr. Smaldone Alsup has served as Chief Scientific Officer and Chief Medical Officer for NDA Group, a regulatory and drug development consulting firm, since March 2016, when NDA Group merged with PharmApprove, LLC. Dr. Smaldone Alsup served as President and Chief Scientific Officer of PharmApprove, LLC, a regulatory communications consultancy firm and division of Taft and Partner, from August 2011 to March 2016. In addition, she served as Chief Executive Officer of Phytomedics, Inc., an early stage company focused on arthritis and inflammation, from 2008 to 2011. Prior to that, Dr. Smaldone Alsup spent over 20 years at Bristol Myers Squibb in roles of increasing responsibility in clinical development, regulatory strategy, and corporate risk management. Dr. Smaldone Alsup currently serves on the board of directors of the publicly-traded companies Blackberry Ltd. and Theravance Biopharma, Inc. and previously served as a member of the board of directors of the publicly-traded company Kalobios Pharmaceuticals, Inc. Dr. Smaldone Alsup holds an M.D. from the Yale School of Medicine and a B.A. in biology from Fordham College. Smaldone Alsup is qualified to serve on our board due to her extensive regulatory and clinical experience in the life sciences industry, senior management experience in several companies in our industry and demonstrated leadership in her field.
As the Independent Director of Arvinas Inc, the total compensation of Laurie Alsup at Arvinas Inc is $544,371. There are 8 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
Laurie Alsup is 66, he's been the Independent Director of Arvinas Inc since 2019. There are no older and 18 younger executives at Arvinas Inc.
Alsup's mailing address filed with the SEC is C/O BLACKBERRY LIMITED, 2200 UNIVERSITY AVENUE EAST, WATERLOO, A6, N2K 0A7.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe a Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: